Pregnant women are increasingly being initiated on antiretroviral therapy either as part of prevention of mother to child transmission of HIV or as purely highly active antiretroviral therapy.In this case report, we describe a 26 year old woman who was 28 weeks pregnant and who presented after 4 weeks of initiation of antiretroviral therapy with a herpes zoster eruption and how the case was man...

INTRODUCTION The Brazilian AIDS Programme success is recognized worldwide, due to its integrated approach of prevention, respect for human rights and to free of charge universal access to state of the art antiretrovirals. CURRENT SITUATION As of 2006, 180,000 people living with AIDS are on HAART with 17 drugs available, receiving medical and laboratory care through the public health system. C...

A follow-up study was conducted on a sample of 120 ethnically diverse HIV-positive men and women first interviewed in 2000. Participant survival and death rates were ascertained from death records and analyses were performed to identify demographic and psychosocial predictors of survival from the original data. Consistent with past studies, factors associated with survival were age, CD4 count, ...

We studied the pharmacokinetics and pharmacodynamics of nelfinavir administered 2 or 3 times per day to human immunodeficiency virus type 1 (HIV-1)-infected children receiving highly active antiretroviral therapy containing nelfinavir. The geometric mean trough concentrations of nelfinavir for the thrice- and twice-daily regimens were 1.55 mg/L and 1.11 mg/L, respectively (P=not significant). N...

The International AIDS Conference held in Durban in 2000 was a watershed for highly active antiretroviral treatment (HAART) in Africa. Since then, HAART in sub-Saharan Africa has been fi rmly on the international agenda, and access to treatment in resource-poor settings has become a top priority. Multiple initiatives were developed to realise the goal of expanding treatment access (The Global F...

The reduction in disseminated NTM infections caused by HAART is one of the success stories in the history of HIV in the developed world. Despite this success, these diseases still occur and may have atypical presentations in patients receiving HAART. Clinicians treating HIV-infected patients must remain familiar with the diagnosis and treatment of these diseases and implement prevention strateg...

This review describes patterns of mortality among adults infected with HIV in the UK and assesses the contributions of late diagnosis of HIV infection and non-HIV-related disease to such mortality. In total, 387 adults with HIV who died between 1 October 2004 and 30 September 2005 after receiving care at 90 clinical centres in the UK were reviewed. Causes of death and scenarios accounting for d...

Background A panorama of mucocutaneous manifestations is produced by HIV infection which correlates with the degree of immunodeficiency. Viral, bacterial and fungal infections, as well as inflammatory skin diseases, have all been reported to increase as CD4 T cells are depleted. Since the introduction of HAART, there has been a dramatic decrease in the incidence of HIV associated dermatoses. Ho...

Highly active antiretroviral therapy (HAART) can reduce plasma HIV-1 levels to below the detection limit. However, due to the latent reservoir in resting CD4(+) cells, HAART is not curative. Elimination of this reservoir is critical to curing HIV-1 infection. Agents that reactivate latent HIV-1 through nonspecific T cell activation are toxic. Here we demonstrate in a primary CD4(+) T cell model...

By 2015, it is estimated that nearly half of those living with HIV in the US will be 50 years of age and older. This dramatic change in the demographics of this clinical population represents unique challenges for patients, health care providers, and society-at-large. Fortunately, because of highly active antiretroviral therapy (HAART) and healthy lifestyle choices, it is now possible for many ...